Please assess the completion status of the following clinical trial:

Trial Title: A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with moderate to severe COPD, with a post bronchodilator FEV1 of 40 to 80% of predicted and FEV1/FVC ratio of ≤0.70.~* They must have a baseline increase in FEV1 of \>150 mL following four puffs of salbutamol.~* They must have at least a 10 pack-year smoking history, and may be either a current or former smoker.~Exclusion Criteria:~* Patients must be clinically stable without recent COPD exacerbations or hospitalisations.~* They must not have uncontrolled disease or chronic heart failure.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- RPL554 100 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of either RPL554 100mcg via metered dose inhaler.~Part B: not applicable
- RPL554 300 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of RPL554 300mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 300mcg via metered dose inhaler in crossover fashion.
- RPL554 1000 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of RPL554 1000mcg via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
- RPL554 3000 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of either RPL554 3000mcg via metered dose inhaler.~Part B: Patients receive repeat doses of RPL554 3000mcg via metered dose inhaler in crossover fashion.
- RPL554 6000 mcg (Type: EXPERIMENTAL): Part A: Patients receive 1 dose of either RPL554 6000mcg via metered dose inhaler.~Part B: not applicable
- RPL554 Placebo (Type: PLACEBO_COMPARATOR): Part A: Patients receive 1 dose of RPL554 placebo via metered dose inhaler. Part B: Patients receive repeat doses of RPL554 placebo via metered dose inhaler in crossover fashion.

Based on this trial design, predict the completion outcome and termination type (if applicable).